Wednesday, 29 February 2012

Bring on the Biomarkers!

I have pinched this title from a slide shown by Charlie Swanton at the First London Cancer Breast Study Day earlier this week! He was one of about a dozen speakers and his session was on a personalised approach to breast cancer treatment. Back to last year's theme of stratified medicine.

He was making the point that predicting drug response and the whole issue of multi-drug resistance are some of the challenges of the personalised approach. The genomics revolution makes it possible to make treatment or trial eligibility decisions fairly quickly based on sequencing from a single biopsy sample. But there is a question as to whether this is the best approach.

Looking at mutations found in samples from primary and secondary tumours shows that while some are ubiquitous, many are not; in fact, the majority are not. Intra-tumour heterogeneity means that drug response can't always be predicted from the sequencing of a single sample.

All this, he suggested, means that the traditional model of linear evolution of cancer is not helpful. Instead, tumours and their evolution are more like trees with branches going off in different directions and then themselves branching. Some tumour-trees have long trunks, while in others the branching starts much lower down. This goes some way to explaining why sometimes we don't see the expected response to a particular drug.

Another reason why stratified medicine is so important.

Tuesday, 21 February 2012

The Light and The Dark

A major difficulty with life here in the Land of New Normal is that even while I'm counting out my reasons to be cheerful there comes difficult news.

Over the last few weeks we have lost two of our international bloggers and, more recently and closer to home, one of the North East girls to this horrible disease.  And still close to home there has been bad news for a couple more.

Life seems somehow sharper here. The sadness surrounding the losses and grim news is painfully deep. But the breath-taking beauty of a morning drive past the diamond-sparkly frost-on-snow fields, hedges and trees the weekend before last was certainly heightened. The friendships that we form in this sisterhood that was thrust upon us are precious and life-giving, but when those very friends are taken from us the grief is profound.

Monday, 16 January 2012

Reasons to be Cheerful

Throughout my life, as well as keeping a somewhat sporadic journal, I have made scrapbooks of significant projects and events.  It was therefore no surprise that after the diagnosis of breast cancer I was collecting relevant photos and quotations as well as scribbling away in my journal. In January 2010 I assembled my Year 1 scrapbook and this time last year was preparing the next one. Now I am thinking about and reviewing Year 3 and it is a cathartic process.

These are not really scrapbooks in the modern sense with beautifully laid out decorative pages (although thanks to one of my Storm Rider friends I'm getting there), but they are a combination of journal extracts, photos and mementos of the things I've done during the year. At the end of the one for Year 1 I noted the number of miles I travelled for treatment and the time I spent at medical appointments. It made interesting reading and was useful in providing one of the consultants at our breast unit with ammunition for his campaign to make radiotherapy available more locally.

Year 2 was complicated by the genetics referral and participation in the screening study. There was a slight shift in the way time was spent. In Year 1, once I had surgery behind me I had a large number of shortish treatments and consultations with lengthy waits in late running clinics, while Year 2 saw lengthy appointments with genetic counsellor and study nurse in clinics that generally ran to time. Cancer is certainly a time-consuming business, even when things are going well!

Looking at last year's appointments I can see that things have settled down considerably and hopefully will continue that way now that the study is over. The Year 3 scrapbook will have far more about holidays, family and friends and leisure than it will directly about cancer. Of course, cancer issues (arm/shoulder problems; fatigue; joint, muscle and bone problems, etc.) are still very much live and form part of everyday life but things have taken a different turn. It is now much more about integrating long-term effects and using the experience positively.

The most important positive aspect is the circle of support in the form of the Storm Riders and which is celebrated in the quilt I'm working on. We still have regular contact and are there for each other as difficult situations arise. Just as importantly, we still meet in real and virtual spheres for fun and everyday chat as well as for support.

Another positive thing for me is that if I really do want to do something I am now much less likely to put it off than I used to do. The obvious example is that I have found time (and energy) for curling.

I tend to tolerate less aggravation in my life these days so I'm more reluctant than I was to go along with a course of action that although possibly useful will cause me a headache. It isn't about avoiding hard work and conflict; it is more about ensuring that the benefits are worth the effort. I'm much more aware of looking after my health, both physically and psychologically.

I am definitely not one of those people who say that cancer has brought them so much that is life-enhancing that if they could by magic re-order the past they would still choose to have cancer. I wouldn't choose to have cancer. However, as the fact is that I can't re-order the past, I may as well take from the experience whatever positive aspects I can.

There are some consequences that do provide me with reasons to be cheerful. The most important of these are my changed priorities and the friends I have made as a result, and the strong bonds we share. It may be a club that none of us actually wanted to join but, once compulsorily enrolled, we certainly know how to make the best of it.

Thursday, 15 December 2011

Another Landmark

For the first time since November 2008 I have no letters in the ‘hospital appointments’ file! This won’t last long because within about a week I’ll receive the appointment for this time next year, but it still feels like a hard-earned freedom. A far cry from the times last year when there were at least half a dozen upcoming appointment letters in the file.


The empty file is the result of my check-up this week. The report on my mammogram said that  “only post-treatment changes” showed up and the examination revealed no unexpected problems.  So now I can move to a single annual check-up and mammogram. First it was three monthly, then four, this year it has been two appointments. I still have open access in between appointments if necessary, which gives me a safety net(physical and psychological) should I need one. 


My clinic appointment was for 4.10pm and the clinic was, it goes without saying, running late. A sharp contrast with mammogram appointments which seem to run to time and if you turn up early they will often see you ahead of time. Expecting to wait, I’d taken an absorbing book with me but then had a chat with someone I’d seen in the same clinic last year (worryingly her appointment time was an hour before mine) and discussed whether or not we dared turn up late based on experience – the answer was “no”,  just in case they were running to time and we were then pushed to the end of the day. I also spent some time thinking about the women I’ve met both in person and virtually over the whole BC thing.


It was wonderful to hear good news and until I did, I don’t think I had really realised just how stressed I’d been about it.  Perhaps it was that time in the waiting room where the stress built; at the very least it made it much worse. 


I seem to find planning ahead difficult in the few weeks between the mammogram and the rest of the check-up.  In the first year I found any planning ahead difficult. Year Two was rather disrupted by the genetics and ovarian screening study, not to mention getting my arm/shoulder movement back, and was more about planning around so many appointments than anything else. Generally this year has felt more relaxed, so when this autumn the Storm Riders were planning for a November 2012 get together, I didn’t think twice about it. I didn’t fully realise the significance at the time; it was only last week when I was having difficulty making plans for early January on the basis of “what if …” that I remembered that only weeks before I’d been planning for a year ahead. 


So here I am, entering another year post-diagnosis and having taken another step forward. Okay, for the next few years the end of November and early December are probably not going to be the best time for planning ahead, but outside that window it all looks more promising. Fatigue is still an issue and I have problems with joints, there are other medication side effects, BUT I am feeling much better all round than I did a year ago. I even noticed while curling the other week that I seem to have regained a bit of my (admittedly never good) sense of balance and have become used to the difference in the left/right weight distribution.  


As I reach this three year mark with no evidence of disease (our dear friend NED) I am very aware that some of those I’ve met going through this have not been so fortunate. Some are dealing with recurrence, second primaries or metastatic disease. And it goes without saying that Cat, who died only a few months ago, is very much on my mind this week, together with her family. She was a great support when we did radiotherapy together and I feel that in some way I owe it to her, and to so many others, not to take life for granted but to get on with living it to the full here in the Land of New Normal, whatever this land throws at me.
Carpe Diem!

Thursday, 17 November 2011

More on the NCRI Conference

I have just completed the feedback survey for the conference and when asked what was the most important  thing I'd gained, my answer was: a better understanding of the role of stratified medicine. To a greater or lesser extent it underpinned all of my "top three conference sessions".

As I said in my overview of the event, stratified medicine was a theme that emerged from a number of the sessions covering different cancer sites and treatments. The scene was set for me by an excellent session on the Monday morning and titled simply "Stratified medicine". The first speaker was Albert Bardelli, from University of Torino Medical School, Italy. He spoke about personalised treatment in colorectal cancer, mentioning that one targeted therapy only benefits about 10% of predicted patients in the absence of further selection. He also made the point that it may well be that not all mutations are "equal". He was followed by Jean Charles Soria, from University XI, Paris. This presentation was about selecting the right therapies for lung cancer patients based on predictive molecular markers. He also highlighted the need for molecular input into multi-disciplinary meetings. The final speaker was David Gonzalez de Castro, from the Royal Marsden in London. He made the observation that molecular markers are only of use if the appropriate drugs are available. He then proceeded to provide a kind of checklist:

1. Find the target
2. Know your enemies & friends (+ve and -ve predictive markers)
3. Put the findings into context
4. If it is stubborn, hit it again! And it may be possible to go back to earlier treatments.

The next in my Top Three was later in the day and had a much more lengthy title - Moving Towards a Molecular Rather Than a Risk-based Approach to Selecting Breast Cancer Patients Who Won't Benefit from Standard Treatment. This was hosted by David Cameron from the University of Edinburgh, who pointed out in his introduction that breast cancer is an area where a stratified approach has been validated  in the now routine hormonal and HER2 targeting; with newer therapies now being developed for further sub-groups. John Yarnold from the Royal Marsden spoke first and covered the possibility of reducing the burden of radiotherapy. This was in terms both of optimising hypofractionation, partial breast radiation and dose distribution, and in identifying who doesn't need radiotherapy. He touched upon predictive markers for adverse effects.

Next was Luca Giani from Milan, who pointed out that a one-size-fits-all approach to treatment results in both over and under treatment. He made the points that ER, PR and HER2 status alone don't coincide with the molecular subtypes, and that fewer people benefit from chemotherapy that receive it under current guidelines.

The final speaker for this session was Michael Lisanti from Philadelphia. He presented a parasitic model of cancer with mitachondria powering cancer cells and the possibilities for blocking this activity.

One of the reasons that I found this session particularly interesting is that it presented a sound scientific challenge to the view often seen expressed on breast cancer fora by those having treatment for breast cancer that they want to "throw everything at it". As we all know, treatments have side effects and while some are "only" (!!!) unpleasant, others are life-threatening in the short, medium and long terms. People can and do die as a result of treatment or end up with more limited options in the event of recurrence or metastatic disease. So identifying those for whom a possible treatment is going to have no effect is important. There is no point in "throwing at it" something that will be of no benefit but which carries a serious health risk. I think that is why I find the advances in stratified medicine so exciting.

The last of my Top Three was the Wednesday session on genetic predisposition and the implications for screening, surveillance and management. It considered breast, ovarian, prostate and colorectal cancers. It opened with Douglas Eaton from the University of Cambridge and included mention of one of the studies in which I have taken part. He spoke about the three main areas of genetic risk for breast cancer: the rare high risk mutations (such as the well known BRCA 1 and 2 gene mutations), the rare moderate risk ones and the common low risk mutations (of which 23 have been found so far with more to come). Different loci carry different levels of risk and can also predict ER status. This could possibly be used to inform decisions on the preventative use of drugs such as tamoxifen. Risk with the common low risk mutations is polygenic and the variants combine multiplicatively. Moreover, genetic risk seems to combine multiplicatively with other risk factors (such as mammographic density). About 200 loci for common cancers have been identified so far.

The second speaker was Harry de Koning from Rotterdam. He discussed issues concerning screening starting with the point that screening programmes are directed at those of average risk, relating this particularly to breast and colorectal cancers. In higher risk populations there can be important differences that might suggest different guidelines for different groups. He illustrated this with guidelines for BRCA 1 and 2 mutation carriers. Screening guidelines are the same, but there is evidence to suggest that while adding mammography to MRI for BRCA1 mutation carriers under 40 gives little benefit, it can contribute to detection of breast cancer in BRCA 2 mutation carriers. There is a need for further work on optimal screening for mutation carriers aged over 60.

The final speaker was Mark Robson from Memorial Sloan-Kettering in New York. He spoke about germline information being used to inform local, systemic and follow-up decisions. In particular it can be useful to know the risk of a second primary - not least because reconstruction options may be more limited after radiotherapy. It was interesting to hear him say that at his Centre the prophylactic mastectomy rate is high and although it wasn't always clear that surgical options had been fully discussed, that was driven by the women themselves (who presumably see no need to have lengthy discussions when they have already decided upon their course of action). He also touched upon germline defects being used as therapeutic drug targets. It has been suggested that BRCA 1 mutation cancers might be hyper sensitive to platinum, although that isn't completely clear. They do seem to respond well to taxanes. This is less so for BRCA 2 mutation cancers, where pathological complete responses are less common.

Other aspects were the possibilities of variants being implicated in radiation-induced tumours and in anthracycline cardio-toxicity.


Those were certainly the highlights for me, but I also attended some very interesting plenaries and sessions on screening and prevention, improving cancer survival, survivorship research, and cancer care as disease rather than discipline based. There was a session in which patients shares their experiences of being involved in clinical trials.

I would like to have attended (but couldn't because I was in another session): Improving design and analysis of early phase trials, Raising awareness of cancer research, Lifestyle factors in prevention, Spotlight on survivorship, and Radiotherapy: the quiet revolution.

Monday, 14 November 2011

Conference Part II

The Poster Abstracts catalogue for the recent NCRI Conference listed a total of 738 posters, displayed in two sessions and grouped thematically.  A few had been withdrawn, but clearly there were far too many to see them all by browsing in the time I had available, so I had to be selective.

The Independent Cancer Patients' Voice, a patient advocacy group of which I am a member, had a poster ('Independent Cancer Patients' Voice - speaking clearly and being heard') in Tuesday's session. It gave us an opportunity to meet people and hand out copies of our Year Book.

There were three posters relating to the ovarian cancer screening study I've been in and I was delighted to see that one of them (presenting a decision making model concerning risk reducing surgery) had won one of the NCRI Prize Awards for PhD students submitting an abstract as first author. Congratulations to Jana Witt and team at Cardiff! Of the other two, one looked at the psychological effects of screening in the context of being recalled after an abnormal result which then turned out not to show a problem. The other investigated the reasons prompting women to withdraw from screening and have risk reducing surgery instead.

I was also interested to see another update on the AZURE trial that is looking at adding zolendronic acid to standard adjuvant treatment in primary breast cancer and which suggested a need for further study to look in more detail at the effect of menopausal status.

Others that caught my eye included methods of follow-up; discussing genetic testing with family members; the efficacy of cognitive behavioural interventions to treat menopausal symptoms; increasing recruitment to clinical trials; the provision of information; the prevalence of low vitamin D levels in breast cancer (this one from my own cancer centre) and suggesting that routine testing and, where appropriate, supplementation should be offered.

There was a poster on lifestyle habits and late toxicity after radiotherapy for prostate cancer that I particularly admired for its clarity and beauty of layout.

That is just a brief selection of those I stopped to read.  I could easily have spent a whole morning or afternoon on each of the two sessions looking at the posters and chatting with those presenting them, but there just wasn't enough time for that.

Thursday, 10 November 2011

An Antidote to Pink

I have just returned from this year's National Cancer Research Institute's (NCRI) cancer conference held in Liverpool. After all the hysteria of October it was good to have the opportunity to hear about what is happening across the whole spectrum of cancer research and how this translates to clinical practice. I plan to make a few posts about the conference as I go through my notes and the various bits of paper I picked up, but for now here's a bit of an overview.

There were plenary lectures; workshops, symposia and detailed sessions covering specific interests; posters and abstracts; a trade exhibition; and time for networking. The networking was a chance to catch up with who is doing what and to learn how people and organisations fit into the overall jigsaw of cancer research and practice.

There were also, it goes without saying, social events as part of the networking process. Barts Cancer Institute hosted on Tuesday evening a reception held at The Beatles Story. To be honest, that wasn't a museum I'd have thought of visiting, but it turns out that would have been a mistake. There are interesting period items and room sets and the reception itself was held in an area replicating The Cavern. It was a spectacular place in which to hold a reception and was suitably packed!

There was a considerable consumer presence at this conference (although as you might expect, there was some debate about the expression "consumer"!) with areas set aside specifically for those there on consumer bursaries to meet each other. Consumers also led a few sessions. The NCRI smoothes the way for consumers to attend with a bursary system and by booking accommodation at a hotel opposite the Convention Centre.

The major problem with the conference was the one common to all good conferences, namely choosing which sessions to attend. Sometimes the choice was clear, but on several occasions I really did want to be in two or three places at once.

The theme of stratified medicine, choosing the right treatment for the right patient, came up time and time again across various sites and treatment types. There were some surprises, particularly in the area of chemoprevention and the lack of positive effects from antioxidants. Another surprise was hearing that about 24% of all cancer patients first present as emergencies and that a similar number have been to their GP with their symptoms between three and five times before getting a diagnosis.

There were some exciting developments too. One of these is the Breast Cancer Campaign Tissue Bank, which has had meaningful patient involvement right from the beginning. It is a collaborative project by four of the UK's leading research institutions and there was a demonstration of the online search and request systems at a workshop and reception on Monday evening.

The conference was a packed, worthwhile and enjoyable three days in which I learnt a great deal, met with some very interesting people and thought a bit more about the way in which I would like to contribute to the process of public and patient involvement in cancer research.